Biogen (NASDAQ:BIIB – Free Report) had its price objective decreased by Mizuho from $251.00 to $207.00 in a research note published on Thursday,Benzinga reports. Mizuho currently has an outperform ...

Sage Therapeutics discontinued development of its lead candidate dalzanemdor after a third clinical failure, leading analysts ...

Semiconductor faced a tough 2024 but is poised for significant growth in 2025 and beyond. Read why I remain very bullish on ...

Shares of a company are up 30% after strong Q3 results. Growth accelerating with strong margins. Stock remains attractively ...

During an address to the Bihari diaspora in the US, political strategist Prashant Kishor characterized Bihar as a "failed state," drawing parallels to Sudan and emphasizing the state's dire need ...